Savara
SVRA
4.68
-0.20
-4.10%
Savara
US · SVRA
#3247 by market cap
4.68
-0.20
-4.10%
Live - 5344 symbols - heartbeat 498s ago
· 2026-10-08 10:11
Pre-market
4.88
0.00%
After-hours
4.98
+1.95%
Overnight
4.88
0.00%
- Market cap
- 961.55M
- P/E (TTM)i
- -8.07
- P/Bi
- 6.70
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on SVRA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Key ratios & quality
- Enterprise valuei
- 755.76M
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 0 | 257.00K | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 10.65M | 13.08M | 14.26M | 12.35M | 10.93M | 15.67M | 25.04M | 42.06M |
| Research & development | 37.17M | 38.78M | 35.04M | 28.99M | 27.88M | 44.26M | 78.03M | 81.40M |
| Operating profit | -46.90M | -50.96M | -48.41M | -40.63M | -38.04M | -59.21M | -102.40M | -122.76M |
| Pretax profit | -68.57M | -78.17M | -49.62M | -43.01M | -38.15M | -54.70M | -95.88M | -118.84M |
| Tax | -7.06M | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -61.52M | -78.17M | -49.62M | -43.01M | -38.15M | -54.70M | -95.88M | -118.84M |
| Basic EPS | -2 | -2 | -1 | 0 | 0 | 0 | 0 | -1 |
| Diluted EPS | -1.85 | -1.95 | -0.84 | -0.32 | -0.25 | -0.33 | -0.48 | -0.53 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.25M | 10.66M | 9.63M | 12.53M | 15.57M | 18.99M |
| Research & development | 19.16M | 20.75M | 20.59M | 20.90M | 23.40M | 21.95M |
| Operating profit | -27.65M | -31.44M | -30.26M | -33.42M | -38.14M | -40.97M |
| Pretax profit | -26.64M | -30.40M | -29.56M | -32.24M | -37.28M | -40.23M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -26.64M | -30.40M | -29.56M | -32.24M | -37.28M | -40.23M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.12 | -0.14 | -0.14 | -0.13 | -0.15 | -0.16 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 113.34M | 124.07M | 85.12M | 165.00M | 128.95M | 165.95M | 202.14M | 241.62M |
| Cash & ST investments | 110.83M | 121.76M | 82.19M | 161.17M | 125.88M | 162.32M | 196.33M | 235.70M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 152.29M | 136.20M | 97.75M | 176.60M | 139.78M | 177.56M | 212.88M | 253.44M |
| Total current liabilities | 7.25M | 10.88M | 8.17M | 14.66M | 5.87M | 10.60M | 14.72M | 20.40M |
| Short-term debt | 41.00K | 2.44M | 179.00K | 8.47M | 64.00K | 143.00K | 116.00K | 7.00K |
| Long-term debt | 24.53M | 23.11M | 25.10M | 17.32M | 26.08M | 26.35M | 26.62M | 29.91M |
| Total liabilities | 44,068,000.00 | 34,505,000.00 | 33,362,000.00 | 32,100,000.00 | 31,999,000.00 | 37,192,000.00 | 41,430,000.00 | 50,303,000.00 |
| Total equity | 108.22M | 101.70M | 64.38M | 144.50M | 107.78M | 140.37M | 171.45M | 203.13M |
| Retained earnings | -129.72M | -207.89M | -257.51M | -300.52M | -338.67M | -393.37M | -489.25M | -608.09M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 177.44M | 150.99M | 128.20M | 241.62M | 209.27M | 178.32M |
| Cash & ST investments | 172.50M | 146.44M | 124.39M | 235.70M | 202.77M | 173.03M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 189.32M | 163.77M | 140.92M | 253.44M | 221.65M | 192.14M |
| Total current liabilities | 11.90M | 13.63M | 16.76M | 20.40M | 15.54M | 17.60M |
| Short-term debt | 121.00K | 90.00K | 49.00K | 7.00K | 44.00K | 298.00K |
| Long-term debt | 29.52M | 29.65M | 29.78M | 29.91M | 30.07M | 30.11M |
| Total liabilities | 41,466,000.00 | 43,281,000.00 | 46,538,000.00 | 50,303,000.00 | 45,606,000.00 | 48,478,000.00 |
| Total equity | 147.85M | 120.48M | 94.39M | 203.13M | 176.04M | 143.66M |
| Retained earnings | -515.89M | -546.29M | -575.85M | -608.09M | -645.37M | -685.60M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -39.28M | -45.12M | -39.84M | -40.08M | -34.55M | -51.06M | -89.09M | -101.04M |
| Depreciation & amortization | 526.00K | 1.01M | 693.00K | 367.00K | 167.00K | 77.00K | 130.00K | 87.00K |
| Free cash flow | -39.42M | -45.27M | -43.13M | -40.14M | -34.56M | -51.36M | -89.11M | -101.06M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 46.30M | 54.84M | 2.29M | 122.15M | -3.00K | 82.50M | 117.18M | 135.09M |
| Ending cash balance | 24.30M | 49.80M | 22.88M | 34.01M | 52.10M | 26.59M | 15.13M | 33.18M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -27.19M | -26.26M | -22.53M | -25.06M | -33.05M | -29.75M |
| Depreciation & amortization | 68.00K | 73.00K | 75.00K | -129.00K | 66.00K | 99.00K |
| Free cash flow | -27.19M | -26.28M | -22.53M | -25.06M | -33.10M | -29.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -215.00K | -114.00K | -24.00K | 135.44M | -240.00K | -5.00K |
| Ending cash balance | 19.56M | 17.44M | 16.28M | 33.18M | 38.79M | 41.80M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -54.07 | -74.48 | -59.75 | -41.19 | -30.24 | -44.08 | -61.50 | -63.45 |
| ROA %i | -39.44 | -54.19 | -42.42 | -31.36 | -24.12 | -34.47 | -49.11 | -50.97 |
| ROIC %i | -46.00 | -60.12 | -44.38 | -31.34 | -25.02 | -36.37 | -56.07 | -57.05 |
| 5-year avg ROE %i | -- | -- | -- | -60.65 | -51.95 | -49.95 | -47.35 | -48.09 |
| EBIT margin %i | -- | -- | -18,728.79 | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.63 | 11.40 | 10.41 | 11.26 | 21.98 | 15.66 | 13.73 | 11.85 |
| Quick ratioi | 15.51 | 11.34 | 10.26 | 11.07 | 21.62 | 15.41 | 13.40 | 11.62 |
| Debt / assetsi | 16.13 | 18.76 | 25.87 | 14.60 | 18.70 | 14.92 | 12.56 | 11.80 |
| LT debt / equityi | 22.67 | 22.73 | 38.99 | 11.99 | 24.20 | 18.77 | 15.53 | 14.72 |
| Interest coveragei | -- | -- | -32.48 | -17.85 | -432.52 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | -- | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -75.77 | -99.30 | -78.74 | -63.45 | -79.95 | -105.48 |
| ROA %i | -58.79 | -72.72 | -60.91 | -50.97 | -63.01 | -78.28 |
| ROIC %i | -66.76 | -83.85 | -68.82 | -57.05 | -69.44 | -88.17 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 14.91 | 11.08 | 7.65 | 11.85 | 13.47 | 10.13 |
| Quick ratioi | 14.59 | 10.83 | 7.49 | 11.62 | 13.12 | 9.89 |
| Debt / assetsi | 15.66 | 18.16 | 21.17 | 11.80 | 13.59 | 15.83 |
| LT debt / equityi | 19.97 | 24.61 | 31.55 | 14.72 | 17.08 | 20.96 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Specialty pharmaceuticals within the respiratory system100.00%
Region
United States100.00%
Quote time 2026-10-08 10:11:05 · For reference only, not investment advice and not tailored to your situation.